The author glosses over Holmes’ history as an unpopular high schooler and, later, Stanford dropout, focusing on her early vision of the specialized blood-reading equipment, the rapid evolution of Theranos, and the early skepticism about the device’s efficacy and reliability. His eye-opening reporting on the company’s inaccurate, voided, or corrected test results, as well as the loss of major retail partnerships with Walgreens and Safeway, knocked Theranos off the tech radar and left it irreversibly devastated. While raising $9 billion through a series of aggressive (and falsified) claims and dozens of private investors, the company’s spiking net worth caught Carreyrou’s attention a few years ago. Founded in 2003, when Holmes was just 19, the company’s claim to “fame” was its revolutionary blood-testing system, which touted the detection of everything from high cholesterol to hepatitis C to cancer using only one drop of blood. A deep investigative report on the sensationalistic downfall of multibillion-dollar Silicon Valley biotech startup Theranos.īasing his findings on hundreds of interviews with people inside and outside the company, two-time Pulitzer Prize–winning Wall Street Journal reporter Carreyrou rigorously examines the seamy details behind the demise of Theranos and its creator, Elizabeth Holmes.
0 Comments
Leave a Reply. |